Skip to main content

Table 5 S. aureus bacteremia (SAB)—estimated days of therapy per 100 bed days: one year prior to and one year after implementing selective reporting

From: Staphylococcus aureus - selective reporting of antibiogram results and its impact on antibiotic use: Interventional study with a reference group on the effect of switching from non-selective to selective antibiotic reporting

Antibiotics Prior to implementing selective reporting
n = 86, BD = 943
After implementing selective reporting
n = 81, BD = 946
DOT per 100 BD after vs. prior to#
pat/ DOT/DOT per 100 BD (95%-CI)* pat/ DOT/DOT per 100 BD (95%-CI)* IRR (95%-CI) p
Selectively reported antibiotics
 Flucloxacillin iv + Cefazolin iv 50 / 494 / 52.4 (42.8; 62.0) 72 / 706 / 74.6 (67.5; 81.8) 1.42 (1.16; 1.75) 0.001
 Cefalexin po 2 / 5 / 0.5 (−0.2; 1.3) 3 / 9 / 1.0 (−0.3; 2.2) 1.79 (0.27; 12.01)
 Trimethoprim-sulfamethoxazole 1 / 3 / 0.3 (−0.3; 0.9) 2 / 5 / 0.5 (−0.3; 1.4) 1.66 (0.13; 20.94)
 Clindamycin iv/po 8 / 47 / 5.0 (0.9; 9.0) 6 / 28 / 3.0 (−0.3; 6.2) 0.59 (0.15; 2.34) 0.457
 Sum of above named selectively reported antibiotics 53 / 549 / 58.2 (48.4; 68.1) 74 / 748 / 79.1 (71.4; 86.7) 1.36 (1.12; 1.65) 0.002
Combination therapy only
 Gentamicin + Tobramycin + Amikacin iv 6 / 32 / 3.4 (0.3; 6.5) 5 / 29 / 3.1 (0.3; 5.8) 0.90 (0.25; 3.28) 0.877
 Rifampin iv/po 15 / 124 / 13.1 (6.6; 19.7) 9 / 92 / 9.7 (3.3; 16.2) 0.74 (0.32; 1.70) 0.476
 Fosfomycin iv 2 / 8 / 0.8 (−0.5; 2.2) 1 / 7 / 0.7 (−0.7; 2.2) 0.87 (0.07; 10.47)
No longer reported antibiotics
 Penicillin G + Ampicillin/Amoxicillin iv 2 / 11 / 1.2 (−0.4; 2.8) 1 / 1 / 0.1 (−0.1; 0.3) 0.09 (0.01; 1.00)
 Ampicillin-sulbactam + Amoxicillin-clavunate iv/po 18 / 69 / 7.3 (3.3; 11.3) 2 / 4 / 0.4 (−0.2; 1.0) 0.06 (0.01; 0.25)  < 0.001
 Piperacillin-tazobactam 27 / 128 / 13.6 (7.6; 19.5) 34 / 158 / 16.7 (10.4; 23.0) 1.23 (0.69; 2.19) 0.481
 Cefuroxime iv/po 10 / 68 / 7.2 (2.2; 12.2) 2 / 14 / 1.5 (−1.0; 4.0) 0.21 (0.03; 1.28) 0.090
 Ceftriaxone iv + Ceftazidime iv + Cefpodoxime po 10 / 46 / 4.9 (1.3; 8.5) 10 / 28 / 3.0 (0.5; 5.4) 0.61 (0.20; 1.84) 0.378
 Imipenem-cilastatin iv + Meropenem iv 11 / 49 / 5.2 (1.6; 8.8) 14 / 69 / 7.3 (3.2; 11.4) 1.40 (0.58; 3.42) 0.455
 Ciprofloxacin + Levofloxacin + Moxifloxacin iv/po 14 / 78 / 8.3 (3.7; 12.9) 12 / 79 / 8.4 (3.1; 13.6) 1.01 (0.44; 2.33) 0.982
 Vancomycin iv 13 / 44 / 4.7 (1.8; 7.5) 7 / 31 / 3.3 (−0.3; 6.8) 0.70 (0.20; 2.43) 0.577
 Linezolid iv/po 2 / 13 / 1.4 (−0.9; 3.7) 2 / 8 / 0.8 (−0.6; 2.3) 0.61 (0.06; 6.76)
 Sum of above named no longer reported antibiotics 70 / 506 / 53.7 (44.6; 62.7) 58 / 392 / 41.4 (31.4; 51.5) 0.77 (0.57; 1.04) 0.087
 Patients with therapy adaption to intravenous flucloxacillin/cefazolin on day 2–4, n (%) 36 (41.9%) 62 (76.5%)   < 0.001 ##
  1. Follow up to a maximum of 14 bed days per patient (except early exit because of death, discharge or hospital transfer)
  2. *Pat/ DOT/DOT per 100 BD (95%-CI): number of patients, days of therapy (DOT), days of therapy per 100 bed days (BD) with 95%-conifdence interval estimated by Poisson regression;
  3. #Poisson regression, incidence rate ratio (IRR) with 95%-confidence interval (CI) and p-value (p), p-values < 0.05 in bold. In case of less than 5 patients in both periods no statistical test was performed
  4. ##Exact Fisher-test